ArticleCureus2025
MicroRNA-Based Markers of Oral Tongue Squamous Cell Carcinoma and Buccal Squamous Cell Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic significance of NTMT1 and its association with tumor progression in oral squamous cell carcinoma.Frontiers in oncology · 2026Article
- Field cancerization in women without conventional risk factors: insights from a case-cohort study.Frontiers in oral health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Oral cancers, including oral tongue squamous cell carcinoma (OTSCC) and buccal squamous cell carcinoma (BSCC), are known to be widespread and can progress aggressively within the oral cavity. Objective The primary aim of this study is to identify microRNA (miRNA)-based markers for OTSCC and BSCC. Materials and methods This observational study was conducted at Northampton General Hospital from January 2024 to December 2024. A total of 150 patients were recruited, and clinical and demographic data were collected, including age, gender, smoking and alcohol consumption history, tumor stage, and grade. Patients were randomly assigned to either the OTSCC or BSCC group using a computer-generated random sequence. Tumor tissue samples from both groups were obtained through biopsy or surgical resection for miRNA analysis. Results Data were collected from 150 patients, with a mean age of 55.4 years, slightly higher in the BSCC group. Males comprised 60% of the cohort, and smoking history was more prevalent in BSCC (73.3%) than in OTSCC (66.7%). Advanced tumor stages (III-IV) were predominant in both groups (61.3% overall), while comorbidities and a family history of cancer were observed in 36.7% and 22.0% of patients, respectively. MiR-21 demonstrated high diagnostic accuracy (area under the curve >0.90) and was independently associated with poor survival outcomes in both cancer types (p < 0.001). Functional analyses linked these miRNAs to key oncogenic pathways, including cell proliferation and metastasis. Conclusions miRNA-based markers, particularly miR-21, show significant potential for enhancing the diagnosis and prognosis of OTSCC and BSCC. Further studies are required to validate these findings and investigate their therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.